Rifabutin

EXPERIMENTAL DRUGS / POTENTIAL ANTIBIOTIC THERAPIES AGAINST M. ULCERANS

Rifabutin

---

CLASS

Rifamycin

---

TARGET PROTEIN

RNA synthesis through interfering with bacterial RNA-polymerase

---

MECHANISM OF ACTION

Bactericidal (act on mycobacteria by inhibiting RNA synthesis through interfering with bacterial RNA-polymerase)

---

DRUG INTERACTION PHASE (APPROVED, INVESTIGATIONAL, EXPERIMENTAL)

Investigational

---

MODE OF ADMINISTRATION

Oral

---

LINK TO PUBMED

https://pubmed.ncbi.nlm.nih.gov/32091697/

https://pubmed.ncbi.nlm.nih.gov/9593357/

---

SIMILAR TARGETS IN OTHER SPECIES

DNA-directed RNA polymerase subunit alpha ~ Escherichia coli (strain K12)

---

DRUG BANK ID

DB00615

---

EXTERNAL LINKS

Human Metabolome Database HMDB14753

KEGG Drug D00424

KEGG Compound C07235

PubChem Compound 6323490

PubChem Substance 46506468

ChemSpider 10482168

BindingDB 50237607

RxNav 55672


ChEBI 45367


ChEMBL CHEMBL444633

ZINC ZINC000169621215

Drugs.com  Drugs.com Drug Page  https://www.drugs.com/cdi/rifabutin.html

Wikipedia Rifabutin

---

REFERENCE

Yotsu, R. R., Richardson, M., & Ishii, N. (2018). Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease). Cochrane Database of Systematic Reviews, 2018(8). https://doi.org/10.1002/14651858.CD012118.pub2



Pluschke, G., & Röltgen, K. (2019). Buruli ulcer: Mycobacterium ulcerans disease. In Buruli Ulcer: Mycobacterium ulcerans Disease. https://doi.org/10.1007/978-3-030-11114-4

---